AI-Driven Drug Discovery Summit 2026

The AI-Driven Drug Discovery Summit returns to Boston for its 2026 edition, opening on 27 October, and sits squarely at the intersection of machine learning and pharmaceutical R&D. Hosted in the dense biotech corridor of Greater Boston, it draws computational chemists, data scientists, discovery biologists and R&D leaders from pharma, biotech and the AI-tooling companies that serve them, all focused on turning algorithmic promise into validated drug candidates.

The summit's remit follows the discovery pipeline end to end: applying AI and machine learning to target identification and validation, generative and structure-based molecule design, lead optimisation, predictive ADMET and toxicology, and the data and infrastructure challenges of getting models into real laboratory workflows. The recurring tension it addresses is the gap between impressive in-silico results and reproducible, developable assets — so sessions tend to foreground case studies, benchmarking and honest discussion of where AI does and does not yet move the needle. For attendees the value lies in comparing approaches across organisations that rarely share methods publicly, and in meeting the platform and foundation-model providers reshaping early discovery. As an industry summit rather than an academic conference, the emphasis is on translational application and partnership-building. Programme, speaker line-up and registration are published on the organiser's event site, worth checking for the confirmed agenda and venue ahead of booking.